Search company, investor...
Genocea Biosciences company logo

Genocea Biosciences

Founded Year




Total Raised


Date of IPO


Market Cap




About Genocea Biosciences

Genocea Biosciences is harnessing the power of T cell immunity to develop the next generation of vaccines. The company is working to create vaccines that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective and long-Aterm immunity against a wide array of diseases. Genocea designs vaccines using ATLAS, its technology platform. Genocea quickly identifies T cell antigens to induce broader and more powerful immune responses than existing vaccines. The company can recreate in vitro the T cell immune responses of hundreds of humans to thousands of potential antigens to identify a small number of proteins appropriate for testing as vaccine candidates.

Headquarters Location

161 First Street

Cambridge, Massachusetts, 02139,

United States


Missing: Genocea Biosciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genocea Biosciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Genocea Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genocea Biosciences is included in 2 Expert Collections, including Cancer.



1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Genocea Biosciences Patents

Genocea Biosciences has filed 21 patents.

The 3 most popular patent topics include:

  • Immune system
  • Immunology
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Vaccines, Immunology, Immune system, Pneumonia, Streptococcaceae


Application Date


Grant Date



Related Topics

Vaccines, Immunology, Immune system, Pneumonia, Streptococcaceae



Latest Genocea Biosciences News

Genital Herpes Market to Exhibit Growth at a CAGR of 3.2% by 2032 | DelveInsight

Nov 21, 2022

| DelveInsight News provided by Share this article Share this article The genital herpes market is expected to grow significantly owing to the increase in diagnosed genital herpes cases per year, awareness, and anticipated launch of emerging therapies by key players such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, GlaxoSmithKline, and others. LAS VEGAS, Nov. 21, 2022  /PRNewswire/ -- DelveInsight's Genital Herpes Market Insights  report includes a comprehensive understanding of current treatment practices, genital herpes emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 8MM [the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), Japan, and China]. Key Takeaways from the Genital Herpes Market Report As per DelveInsight analysis, the genital herpes market size in the 7MM + China was approximately USD 1,125 million in 2021. According to the assessment done by DelveInsight, the estimated total genital herpes diagnosed cases in the 7MM + China was approximately 1.6 million in 2021. Leading genital herpes companies such as AiCuris, United BioPharma, Heidelberg ImmunoTherapeutics, Genocea Biosciences, Agenus, Fresh Tracks Therapeutics, Sanofi, GlaxoSmithKline, and others are developing novel genital herpes drugs that can be available in the genital herpes market in the coming years. The promising genital herpes therapies in the pipeline include AIC-316 (pritelivir), UB-621, HDIT101, SIMPLIRIX (GSK208141), GEN-003, HerpV (AG-707), VCL-HB01, SP-0148, and others. In August 2022, Rational Vaccines Inc. announced the start of an observational clinical trial to determine the baseline characteristics of patients with recurrent symptomatic herpes simplex virus type 2 infection (HSV-2). Discover which therapies are expected to grab the major genital herpes market share @ Genital Herpes Market Report Genital Herpes Overview Genital herpes is a chronic sexually transmitted infection (STI) characterized by genital blisters and open sores (lesions). Among the genital herpes causes, two types of herpes simplex virus (HSV), HSV-1 and HSV-2, play an important role. The virus becomes active for a short period before going dormant; when active, it travels to the surface of the infected area (skin or mucous membrane) and replicates itself. This is referred to as "shedding" because the viruses can rub off and spread to another person at this stage. In most cases, genital herpes is asymptomatic, but it can also present with mild genital herpes symptoms, leading to the infection going unnoticed. Most genital herpes transmission occurs from asymptomatic patients or patients whose genital herpes symptoms have not been recognized. Due to the inaccuracy of diagnostic tests, genital herpes diagnosis is difficult, especially in patients with no genital herpes symptoms. Genital Herpes Epidemiology Segmentation DelveInsight estimates that there were approximately 1.6 million diagnosed cases of genital herpes  in the 7MM + China in 2021. Among the 8MM, the highest number of prevalent HSV-infected cases was observed in China in 2021. The genital herpes market report  proffers epidemiological analysis for the study period 2019–2032 in the 7MM + China segmented into: Prevalent HSV infected cases  Genital Herpes cases, by gender  Diagnosed Genital Herpes cases per year Total recurrent cases of Genital Herpes  Treated patient pool of Genital Herpes Download the report to understand which factors are driving genital herpes epidemiology trends @ Genital Herpes Epidemiological Insights Genital Herpes Treatment Market  Genital herpes treatment is assigned to patients based on the type of HSV that caused the infection and the number of episodes of infection. Different regimens are recommended for the first clinical episode, episodic therapy and suppressive therapy; different therapeutic regimens are recommended for HSV-1 and HSV-2. There are also specific guidelines for managing complications associated with genital herpes, such as HIV infection, antiviral-resistant HSV infection, herpes during pregnancy, and neonatal pregnancy. Although genital herpes has no known cure, but daily use of antiviral medications can prevent or shorten outbreaks. Antiviral medications can also reduce the likelihood of it spreading to others. For genital herpes treatment, effective oral antiviral medications are available. These genital herpes medications provide clinical benefits but do not cure the disease. These medications can be used for either short-term or long-term suppressive therapy. The oldest and most researched genital herpes medication is acyclovir (ZOVIRAX), a guanosine analog that inhibits viral DNA synthesis. It has a low bioavailability and a short half-life, requiring frequent dosing. Valacyclovir (VALTREX), a prodrug metabolizing to acyclovir, has higher bioavailability than acyclovir and requires less frequent dosing. Moreover, FAMVIR (famciclovir) is a purine analog with high bioavailability. They all have rare, similar side effects, such as nausea, vomiting, headache, and diarrhea. Genital Herpes Pipeline Therapies and Key Companies AIC-316 (pritelivir): AiCuris Genital herpes is a common sexually transmitted disease. As the population of various geographies grows, so does the prevalence of health issues worldwide. As a result of the increasing prevalence of diseases, the genital herpes market will increase in the coming years. In addition to a rapidly growing population, the increased awareness and diagnosis would present appealing potential opportunities for the genital herpes market. However, there are significant unmet needs in the genital herpes market. Although genital herpes is an STI, it has a significant impact on patients' mental and social health and sexual health. Furthermore, the diagnostic tests for genital herpes are inaccurate. Most HSV-infected people are asymptomatic or have very mild symptoms that go unnoticed or are misdiagnosed as another skin condition. Another significant gap in the genital herpes market is the lack of preventive and curative therapies. Moreover, the emerging pipeline for genetic herpes is also not very strong, with only a few therapies in development, most of which are being developed for symptom management and symptom reduction. As a result, in the current genital herpes market, there is no preventive or curative genital herpes treatment among emerging drugs. Furthermore, several generics and off-label drugs are available on the genital herpes market. The availability of generics for these and previously marketed products, as well as off-label therapies, may stymie sales of new therapies in the genital herpes market. Hence, these factors may affect the growth of the genital herpes market. Report Metrics Chlamydia Infections Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chlamydia infections companies, including Melinta Therapeutics, Abera Bioscience, Prokarium, Blue willow Biologics, Microbiotix, Abivax, among others. Human Papillomavirus Infection Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key human papillomavirus infection companies, including Vaccibody As, Genexine, Transgene, Inovio Pharmaceuticals, among others. Human Immunodeficiency Virus Type 1 (HIV-1) Infection Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key human immunodeficiency virus type 1 (HIV-1) infection companies, including United BioPharma, Gilead sciences, Taimed Biologics, Merck, among others. Other Trending Reports About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Additionally, get in touch with our business executive to explore @ Healthcare Due Diligence Services   Contact Us

Genocea Biosciences Frequently Asked Questions (FAQ)

  • When was Genocea Biosciences founded?

    Genocea Biosciences was founded in 2006.

  • Where is Genocea Biosciences's headquarters?

    Genocea Biosciences's headquarters is located at 161 First Street, Cambridge.

  • What is Genocea Biosciences's latest funding round?

    Genocea Biosciences's latest funding round is IPO.

  • How much did Genocea Biosciences raise?

    Genocea Biosciences raised a total of $90.7M.

  • Who are the investors of Genocea Biosciences?

    Investors of Genocea Biosciences include Lux Capital, Polaris Partners, SR One, Morningside Ventures, Auriga and 11 more.

  • Who are Genocea Biosciences's competitors?

    Competitors of Genocea Biosciences include BioDelivery Sciences International, Foamix Pharmaceuticals, Fusion Antibodies, Ceregene, NeoClone and 11 more.

Compare Genocea Biosciences to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

Armgo Pharma

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.


Excelimmune is a biopharmaceutical company specializing in the development of recombinant polyclonal antibodies to create novel therapies for treating disease in humans. This next generation technology is applicable to the treatment of diseases and infections caused by common bacteria, disease-causing proteins and viral pathogens.


Gliknik is a privately held biopharmaceutical company creating new therapies for patients with cancer and immune disorders. Gliknik specializes in the modulation of the immune system to fight disease. The Gliknik clinical compound is the immune modulator GL-0817 for cancer, which is in a randomized, blinded, placebo-controlled study in the prevention of recurrence of high-risk oral cavity cancer.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

NeoClone Logo

NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.